Company intelligence / Profile preview

Triphase Research and Development

San Diego, California, United States

Ownership: Private
Development stage: Phase 1

Overview

TRPH‑222, an antibody-drug conjugate targeting CD22, has completed a Phase I multicenter open-label study in relapsed/refractory B-cell lymphoma. The company’s pipeline also includes small molecule drugs targeting proteasome and WDR5 with preclinical or pending status in solid tumors and AML.

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugates (ADC)Small molecule drugs
Industry: Biotech

Drug pipeline

1 asset

NPI-1387

Discontinued

Partnerships

Celgene Corporation has been a collaborator/sponsor on clinical trials.

Beyond the preview

Go deeper on Triphase Research and Development.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Triphase Research and Development.

Explore the full profile